Abstract 173P
Background
Breast cancer (BC) presents challenges in predicting disease progression despite advancements in treatment and monitoring. Circulating tumor cells (CTCs) were initially seen as promising for prognosis via liquid biopsy, but complexities in their investigation have emerged over the past 15 years. Variability in isolation methods and the absence of universal CTC markers hinder standardization and comparison of research findings. In the present study we focused on CD24 which shows potential as a prognostic marker of BC. This study aims to elucidate the prognostic significance of CD24+ circulating cells in peripheral blood of BC patients.
Methods
The study included 57 patients with invasive breast carcinoma of no special type (IC NST) T1-4N0-3M0-1. Circulating cell phenotypes assessment was carried out by flow cytometry (Novocyte 3000, ACEA Biosciences, USA) using monoclonal antibody cocktail.
Results
In our investigation we utilized epithelial markers EpCAM and cytokeratin 7/8 to assess CTCs, including both metastatic and non-metastatic BC patients. Surprisingly, these markers were insufficient in identifying CTC populations indicative of distant metastasis in BC. However, we made the intriguing discovery of CD45-CD24+ circulating cells lacking epithelial markers EpCAM and CK7/8 associated with distant metastasis. Increased level of CD45-EpCAM-CK7/8-CD24+N-cadherin- circulating cells were observed among patients with established metastases and those who developed metastatic lesions during subsequent monitoring. Furthermore, exceeding a threshold of 218.3 cells per milliliter of peripheral blood before treatment predicted a 12-fold increase in metastatic risk and a 3-fold reduction in DMFS over a 90-month period. The unveiled cell population could originate with equal probability from epithelial cells that have undergone EMT or from immature cells from bone marrow. However, it should be noted that these CCs do not align with any recognized stages of monocyte or neutrophil maturation.
Conclusions
The count of CD45-EpCAM-CK7/8-CD24+N-cadherin- CCs was associated with distant metastasis, as their numbers were elevated in peripheral blood of patients with metastases during the follow-up period.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The study was supported by the Russian Science Foundation (grant #23-15-00135).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
152P - Exploratory biomarker analysis of phase III ASTRUM-004 study: Serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer
Presenter: Caicun Zhou
Session: Poster session 08
153P - 23ME-01473, an Fc-enhanced anti-ULBP6/2/5 antibody, restores anti-tumor NK cell function through NKG2D and FcgRIIIa activation
Presenter: Kim Gerrick
Session: Poster session 08
154P - Phase II study of nivolumab and relatlimab utilizing single cell analysis of circulating T cells reveals immune features associated with response to dual PD-1 and LAG-3 inhibition
Presenter: James Dollar
Session: Poster session 08
155P - The molecular basis of the lymphocyte stability index (LSI): A pan-cancer peripheral biomarker for survival post immune checkpoint blockade (ICB)
Presenter: Robert Watson
Session: Poster session 08
156P - Microbiota-related multiomics to assess the clinical relevance of antibiotics (ATB) in immunotherapy (ICI)
Presenter: Adele Bonato
Session: Poster session 08
157P - Soluble and EV-bound CD27 act as antagonistic biomarkers in patients with solid tumors undergoing immunotherapy
Presenter: Joao Gorgulho
Session: Poster session 08
158P - Patterns of immune-related adverse events in early-phase cancer immunotherapy trials
Presenter: Benjamin Fairfax
Session: Poster session 08
160P - Predicting immune-related adverse events using biomarkers in early-phase cancer immunotherapy trials
Presenter: Benjamin Fairfax
Session: Poster session 08
161P - Fibroblast activation protein (FAP)-CD40 (RO7300490) mediates intratumoral DC maturation and modulation of the tumor microenvironment
Presenter: Ignacio Melero
Session: Poster session 08